Direct Ras G12C Inhibitors: Crossing the Rubicon

Research output: Contribution to journalArticlepeer-review


Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered ‘undruggable’. In 2019 we will see the first clinical results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures.

Bibliographical metadata

Original languageEnglish
JournalBritish Journal of Cancer.
Early online date26 Jun 2019
Publication statusPublished - 2019